Eficacia de la glibenclamida versus la bexaglifocina en disminución de la hemoglobina glicosilada para el tratamiento de la diabetes mellitus tipo 2: revisión sistemática

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) is a chronic disease worldwide that has shown an alarming increase in cases, from 425 million in 2017 to nearly 360 million by 2045, according to the latest reports from the International Diabetes Federation (IDF). Therefore, there is a need for innovative therapeutic options, such as Bexagliflozin and Glibenclamide, both of which have shown promising results in the treatment of T2DM. This systematic review focuses on providing a concrete and detailed overview of the best therapeutic option for treating T2DM. Objectives: To evaluate the efficacy of Glibenclamide compared with Bexagliflozin in reducing glycosylated hemoglobin for the treatment of type 2 diabetes mellitus. Methods: A systematic review was conducted following the PRISMA 2020 guidelines, along with different parameters to ensure the robustness of the results. Results: Glibenclamide has demonstrated greater effectiveness in terms of reducing glycosylated hemoglobin levels, ranging from 1.5% to 2%, compared with Bexagliflozin, which shows a reduction of 0.8% to 1.5%. However, Glibenclamide has greater hypoglycemic effects, which is one of the most important complications associated with this drug. On the other hand, Bexagliflozin offers additional parameters, such as weight loss and cardiovascular benefits. Therefore, the choice between these two medications should be based strictly on the evaluation of the patient's profile, considering all underlying clinical conditions. Keywords: bexagliflozin, type 2 diabetes mellitus, glibenclamide.